Crohn Disease
📧 Sign up to get email alerts when something new happens for Crohn Disease.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-07-31EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.
The EMA has withdrawn Qoyvolma (ustekinumab) from the market.
-
EMA withdrawal · 2026-07-28EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
-
CLINICAL_TRIALS withdrawal · 2026-04-16Clinical Trial Update: Stem Cells for the Treatment of Pouchitis [Phase 1]
The Cleveland Clinic's Phase 1 stem cell trial for pouchitis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-04-15Clinical Trial Update: Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's [Phase 1]
The ClinicalTrials.gov entry shows a Phase 1 trial investigating mesenchymal stem cells for pouch fistulas in Crohn's disease has been withd…
-
CLINICAL_TRIALS withdrawal · 2026-01-27Clinical Trial Update: AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) [Phase 1]
A Phase 1 trial evaluating allogeneic human mesenchymal stem cells for fistulizing Crohn's disease via perifistula injections has been withd…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-12-18EMA Withdrawn: Absimky (ustekinumab) — Accord Healthcare S.L.U.
EMA has withdrawn Absimky (ustekinumab) from Accord Healthcare S.L.U., affecting its use for Crohn disease and ulcerative colitis.
-
EMA withdrawal · 2025-09-08EMA Withdrawn: Eksunbi (ustekinumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn Eksunbi (ustekinumab) from the European market as of 23 May 2025, affecting indications for Crohn's disease, ulcerativ…
-
CLINICAL_TRIALS withdrawal · 2025-07-09Clinical Trial Update: Improving Patient Outcomes Through the Implementation of an IBD Biologic Care Pathway [NA]
Clinical trial evaluating an inflammatory bowel disease biologic care pathway to improve patient outcomes has been withdrawn. The study targ…
-
CLINICAL_TRIALS withdrawal · 2025-07-08Clinical Trial Update: A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer
A clinical trial evaluating cancer incidence in people treated with darvadstrocel for Crohn's disease with complex perianal fistula has been…
-
CLINICAL_TRIALS withdrawal · 2025-06-11Clinical Trial Update: CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
The clinical trial of certolizumab pegol (CDP-870) in adults with Crohn's disease is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease
A pilot clinical trial studying the role of gut flora in Crohn's disease sponsored by ProgenaBiome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease [Phase 2]
A Phase 2 study evaluating JNJ-64304500 as add-on therapy for active Crohn's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-10Clinical Trial Update: Immune Ablation and Stem Cell Support for Crohn's Disease [Phase 2]
A Phase 2 clinical trial of immune ablation and stem cell support for Crohn's disease has been withdrawn.
-
EMA withdrawal · 2024-12-13Alofisel withdrawn from the EU market
The EMA has withdrawn Alofisel from the EU market. It determined that the medicine's benefit in Crohn's disease is no longer demonstrated.
-
CLINICAL_TRIALS withdrawal · 2024-11-12Clinical Trial Update: 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients [NA]
The clinical trial investigating 90Second IBD for improving self-efficacy and quality of life in Crohn's disease and ulcerative colitis has …
-
CLINICAL_TRIALS withdrawal · 2024-07-31Clinical Trial Update: Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients [Phase 2, Phase 3]
The Phase 2b/3 study of ABX464 in moderate to severe active Crohn's disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-04-18Clinical Trial Update: SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery [Phase 3]
A Phase 3 trial assessing aspirin versus standard of care for VTE prophylaxis after IBD surgery has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-02-01Clinical Trial Update: The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer [Phase 3]
A Phase 3 trial evaluating topical mesalazine sustained-release tablets for Crohn's disease with oral ulcers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-08-09Clinical Trial Update: Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients [Phase 4]
A Phase 4 trial comparing Exclusive Enteral Nutrition with infliximab in Chinese patients with Crohn's disease was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-06-23Clinical Trial Update: A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 trial investigating Certolizumab Pegol in children and adolescents with Crohn's disease was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-10-27Clinical Trial Update: Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study [Phase 4]
Phase 4 post-marketing study of Vedolizumab-4002 investigating drug–drug interactions has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-08-20Clinical Trial Update: Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis [Phase 4]
A Phase 4 trial evaluating an antibiotic regimen targeting Mycobacterium avium paratuberculosis for Crohn's disease has been withdrawn.
-
EMA withdrawal · 2020-03-25EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.
-
CLINICAL_TRIALS withdrawal · 2020-03-25Clinical Trial Update: Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease [Phase 2, Phase 3]
A clinical trial investigating cannabidiol as an adjunct therapy for Crohn's disease (Phase 2/Phase 3) has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-01-18Clinical Trial Update: Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD [Phase 4]
A phase 4 clinical trial investigating escalating adalimumab for prevention of relapse in inflammatory bowel disease has been withdrawn.